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ABSTRACT: All healthy humans have high levels of natural anti-
α-galactosyl (α-Gal) antibodies (elicited by yet uncharacterized
glycotopes), which may play important roles in immunoglycomics:
(a) potential protection against certain parasitic and viral zoonotic
infections; (b) targeting of α-Gal-engineered cancer cells; (c)
aiding in tissue repair; and (d) serving as adjuvants in α-Gal-based
vaccines. Patients with certain protozoan infections have specific
anti-α-Gal antibodies, elicited against parasite-derived α-Gal-
bearing glycotopes. These glycotopes, however, remain elusive
except for the well-characterized glycotope Galα1,3Galβ1,4Glc-
NAcα, expressed by Trypanosoma cruzi. The discovery of new
parasitic glycotopes is greatly hindered by the enormous structural
diversity of cell-surface glycans and the technical challenges of classical immunoglycomics, a top-down approach from cultivated
parasites to isolated glycans. Here, we demonstrate that reversed immunoglycomics, a bottom-up approach, can identify parasite
species-specific α-Gal-bearing glycotopes by probing synthetic oligosaccharides on neoglycoproteins. This method was tested here
seeking to identify as-yet unknown glycotopes specific for Leishmania major, the causative agent of Old-World cutaneous
leishmaniasis (OWCL). Neoglycoproteins decorated with synthetic α-Gal-containing oligosaccharides derived from L. major
glycoinositolphospholipids served as antigens in a chemiluminescent enzyme-linked immunosorbent assay using sera from OWCL
patients and noninfected individuals. Receiver-operating characteristic analysis identified Galpα1,3Galfβ and Galpα1,3Galfβ1,3-
Manpα glycotopes as diagnostic biomarkers for L. major-caused OWCL, which can distinguish with 100% specificity from
heterologous diseases and L. tropica-caused OWCL. These glycotopes could prove useful in the development of rapid α-Gal-based
diagnostics and vaccines for OWCL. Furthermore, this method could help unravel cryptic α-Gal-glycotopes of other protozoan
parasites and enterobacteria that elicit the natural human anti-α-Gal antibodies.
KEYWORDS: anti-α-Gal antibodies, biomarkers, bioorganic chemistry, cutaneous leishmaniasis, glycoinositolphospholipids,
Leishmania major, neoglycoproteins, oligosaccharide synthesis
■ INTRODUCTION
Old-World primates, including humans, do not express α-
galactose (α-Gal) in their glycoproteins due to the inactivation
of the α1,3-galactosyltransferase gene in ancestral Old-World
primates 20−30 million years ago.1 Therefore, humans are
capable of producing anti-α-galactosyl antibodies (anti-α-Gal
Abs) against α-Gal-bearing antigens. Due to continuous
stimulation by antigenic α-Gal-containing lipopolysaccharides
of enterobacteria,2 high titers of anti-α-Gal Abs are maintained
life-long in normal human serum (NHS).3 The exact structures
of the glycotopes that collectively elicit these anti-α-Gal Abs
are yet to be identified and structurally characterized. While it
is unknown whether natural anti-α-Gal Abs have a distinct
physiological purpose, they are important players in
immunoglycomics due to their cross-reactivity with other α-
Gal-containing glycans. For example, their cross-reactivity with
the Galili trisaccharide, Galα1,3Galβ1,4GlcNAcβ, which is
expressed by all mammals other than Old-World primates,1 is
responsible for the hyperacute rejection of porcine xenografts.4
On the other hand, they are likely to interfere with the
transmission of α-Gal-containing enveloped animal viruses to
humans, thus protecting humans from zoonotic viral diseases.5
The binding of natural anti-α-Gal Abs from NHS (or from
α1,3-galactosyltransferase-knockout mice or pigs) to Galα1,3-
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Galβ-containing glycans has been exploited in a number of
biomedical contexts.5 Examples include the anti-α-Gal Abs-
mediated recruitment of macrophages by α-Gal nanoparticles
in wound healing and tissue repair, the decoration of cancer
cells and viral and bacterial pathogens with α-Gal-containing
bifunctional molecules to increase their antigenicity and cause
their destruction by the immune system,5−7 and the develop-
ment of α-Gal-expressing tumor cells as anticancer vaccines.8
Furthermore, α-Gal residues of glycoengineered protein- and
virus-based vaccines form immunocomplexes with anti-α-Gal
Abs, serving as adjuvants leading to enhanced uptake by
antigen-presenting cells.9 The natural (or NHS) anti-α-Gal
Abs are also known to cross-react with α-Gal-expressing
protozoa, i.e., some Leishmania spp.,10,11 Trypanosoma
cruzi,10,12,13 Trypanosoma brucei,14 and Plasmodium falcipa-
rum,15−17 the causative agents of leishmaniasis, Chagas disease
(CD), African trypanosomiasis, and malaria, respectively.
These antibodies could be the first line of defense to fend
off the establishment of parasitic infections in Old-World
primates.5 In patients with these infectious diseases, parasitic
α-Gal-bearing glycotopes elicit specific anti-α-Gal Abs that
exceed the NHS anti-α-Gal Abs in both concentration and
binding strength and, ultimately, in specificity.10,12,15,18 Knowl-
edge of these glycotopes could open doors for biomedical
applications such as diagnostics and vaccine development.
Unfortunately, the exact structures of these glycotopes are
unknown, with the exception of the well-established T. cruzi
glycotope Galα1,3Galβ1,4GlcNAcα, which makes up to ∼10%
of the parasite’s α-Gal-containing mucin O-glycans.18 The
identification of parasitic α-Gal glycotopes by classic
immunoglycomics requires cultivation of large amounts of
parasites (sometimes, unfeasible depending upon the parasite
life-cycle stage), and isolation and analysis of the cell surface
glycans, which require a vast array of analytical methods, such
as glycoproteomics, enzymatic and/or chemical release and
fluorescent labeling of glycans, glycoprofiling by various high-
resolution mass spectrometry (HR-MS)-based approaches, and
nuclear magnetic resonance (NMR), among others.19−21 This
top-down approach is further complicated by the enormous
structural diversity of parasite glycocalyces.22 To get around
these technical challenges and limitations, we pursued a
bottom-up approach, akin to reversing the classical immuno-
glycomics approach: based on known or potential parasitic α-
Gal-glycotopes, glycans of different sizes are synthesized,
coupled to a carrier protein, and their antigenicity is
interrogated with sera from patients. Here, we show that this
reversed immunoglycomics approach can lead to the discovery
of novel parasitic α-Gal glycotopes. We selected Old-World
cutaneous leishmaniasis (OWCL) as a proof of concept for
two reasons: (a) L. major, one of the causative agents of
OWCL, abundantly expresses α-Gal-bearing type-2 glycoino-
sitolpholipids (GIPLs) whose structures are known23 and are
likely to contain immunodominant glycotopes; (b) the
discovery of L. major glycotopes would be impactful because
they could serve as biomarkers (BMKs) for OWCL, for which
currently no molecular BMKs exist.
Cutaneous leishmaniasis (CL) is a vector-borne infectious
disease caused by different species of the protozoan parasite
Leishmania, and is transmitted by infected female sandflies.24
OWCL is endemic to the Mediterranean basin, Middle East,
and Central Asia, where approximately 700 000 new infections
are reported annually.25 While CL is usually not life-
threatening, it causes large disfiguring skin ulcers, often
associated with secondary infections, that may take months
to years to heal, and the scarring often leads to social stigma
and depression.26 In Northern Africa and the Middle East, the
two most prevalent OWCL-causing Leishmania species are L.
major and L. tropica.27 In the absence of a protective OWCL
vaccine, the only feasible way to control the disease is through
chemotherapy.28 However, treatment responses vary depend-
ing on the infecting parasite species.24,29 For example, topical
azoles/fusidic acid ointments are effective for treating OWCL
caused by L. major but are ineffective for L. tropica.29 This
underscores the need for a species-specific diagnosis of
OWCL.24
OWCL is commonly diagnosed by inspection of skin lesions,
but the lesions closely resemble other skin conditions, such as
atopic dermatitis (eczema), skin cancer, and Hansen’s
disease.28,30 Other diagnostic methods include the detection
of Leishmania from skin lesions by microscopy, histopathology
(amastigotes), and in culture (promastigotes), as well as
serology using whole parasite lysate as the antigen.24,20
However, the limited sensitivity and specificity of these
methods do not always accurately diagnose OWCL20 and
cannot differentiate between infecting Leishmania species.24
The polymerase chain reaction has an extraordinary sensitivity
and can differentiate between species, but it is expensive,
technologically demanding, and often unavailable in clinical
laboratories in developing countries,28,31 where an affordable,
species-specific diagnostic test is needed the most. To put this
into further context, the continuing unrest in the Middle East,
particularly in Syria, Afghanistan, and Iraq, has resulted in a
massive displacement of individuals who are potentially
infected with L. major or L. tropica.32 Many of these individuals
live in CL-endemic refugee settings and areas where diagnostic
capabilities are limited. This population group would
particularly benefit from a robust, diagnostic species-specific
OWCL assay to inform best drug treatment options.
■ RESULTS AND DISCUSSION
The glycocalyx of Leishmania parasites is predominantly
composed of GIPLs, as well as lipophosphoglycans (LPGs)
and glycosylphosphatidylinositol (GPI)-anchored proteins,
such as GP63 and proteophosphoglycans (PPGs).23,33−36 L.
major synthesizes highly abundant type-2 GIPLs (GIPL-1,
GIPL-2, and GIPL-3), which contain a β-galactofuranosyl (β-
Galf) (GIPL-1) or α-galactopyranosyl (α-Galp) (GIPL-2 and
GIPL-3) residue at their terminal, nonreducing ends.23 There
is a considerable body of evidence that these unusual sugars
expressed in L. major and in other pathogens, such as T. cruzi,
fungi, and enterobacteria, are highly immunogenic to human
hosts because they are either cryptic or not normally expressed
(α-Galp), or entirely absent (β-Galf) on human cells.23,37−44
On the other hand, the main GIPLs of L. tropica belong to the
α-mannose-terminating GIPLs iM2, iM3, and iM4.34 We
hypothesized that terminal oligosaccharide partial structures of
type-2 GIPLs of L. major may be immunodominant glycotopes
that are serologically exploitable as diagnostic BMKs
specifically for OWCL caused by L. major and distinguishable
from OWCL caused by L. tropica, as well as from non-OWCL
dermatological (heterologous) diseases, such as atopic
dermatitis (eczema), and bacterial and fungal infections. To
address this hypothesis, specific L. major-derived glycan partial
structures needed to be synthesized and immunologically
evaluated.
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Here, we present reversed immunoglycomics as a combined
chemical and serological approach to discover specific glycan
BMKs suitable for the diagnosis of L. major infection and for
the distinction from L. tropica infection and heterologous
diseases, using synthetic cell surface glycans of the parasite.
Instead of isolating glycoconjugates from large-scale cultivated
parasites and studying their glycoimmunology, we have
reversed this classical immunoglycomics approach by probing
synthetic partial structures of known cell surface glycans for
antibody responses by the highly sensitive chemiluminescent
enzyme-linked immunosorbent assay (ELISA). Our previous
studies showed that the sera of OWCL patients from Saudi
Arabia contain elevated levels of anti-α-Gal IgG antibodies45
that partially recognize simple α-Gal-containing saccharides,
but a specific α-Gal BMK remained elusive.46 Therefore, we
shifted our focus to α-galactopyranose- and β-galactofuranose-
containing saccharides of the terminal, nonreducing glycan
portions of type-2 GIPLs of L. major. The synthesis of a
Figure 1. Target 3-thiopropyl glycosides of Galpα1,3Galfβ (G27SH), Galpα1,3Galfβ1,3Manα (G30SH), and Galpα1,6Galpα1,3Galfβ (G28SH)
derived from type-2 GIPL-2 and GIPL-3 of L. major.
Scheme 1. Synthesis of 3-Thiopropyl Glycosides G27SH, G30SH, and G28SH
aTMS-OTf, DCM, 0 °C to rt, 1 h, MS 4 Å (50−67%). bHF·pyridine, THF, 0 °C then rt, 1 h (65−88%). cTFA/H2O/DCM 1:1:10, rt, 15 min (70−
90%). dAcSH, AIBN or DPAP, THF, UV light (350 nm), 6-12 h (85−93%). eNaOMe, MeOH, rt, 2 h (quant.). fNIS, AgOTf, DCM, 0 °C to rt, 45
min, MS 4 Å (47%). gHF·pyridine (1.2 equiv), THF, 0 °C, 6 h or HF·pyridine (excess), THF, 0 °C, 2 h (60%).
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terminal trisaccharide of type-2 GIPLs and a heptasaccharide
present in LPGs of Leishmania parasites has been reported.47,48
Here, we have developed original syntheses for three type-2
GIPL partial structures with a chemical handle at the reducing
end, allowing for conjugation to a carrier protein. Specifically,
3-thiopropyl glycosides of the GIPL-2-derived glycans
Galpα1,3Galfβ (G27SH) and Galpα1,3Galfβ1,3Manpα
(G30SH), as well as the GIPL-3-derived glycan Galpα1,6Gal-
pα1,3Galfβ (G28SH), were synthesized (Figure 1). Conjuga-
tion of these oligosaccharides to bovine serum albumin (BSA)
produced neoglycoproteins (NGPs) which, unlike the
oligosaccharides by themselves, adhere effectively to ELISA
microplates. These NGPs served as antigens to be evaluated by
chemiluminescent ELISA,45,49 using sera of OWCL patients
from Saudi Arabia with confirmed L. major or L. tropica
infections.
Our synthetic strategy for all three oligosaccharides G27SH,
G30SH, and G28SH relied on (a) the stereoselective α-
galactosylation using Kiso’s 4,6-di-tert-butylsilylene-galactosyl
trichloroacetimidate donor;50,51 (b) an orthogonal protecting
group strategy primarily based on acyl, acetal, and silyl groups;
and (c) the use of 3-thiopropyl glycosides for the conjugation
to maleimide-derivatized BSA.52,53 The synthesis of GIPL-3-
derived trisaccharide G28SH also included a regioselective ring-
opening of the 4,6-O-di-tert-butylsilyene (DTBS) moiety to
gain access to a disaccharide acceptor in a single step.
The synthesis of the three target oligosaccharides G27SH,
G30SH, and G28SH started with the preparation of the
monosaccharide building blocks 1,54 2,55−57 and 3.50 In
order to construct 3-thiopropyl α-D-galactopyranosyl-(1→3)-
β-D-galactofuranoside G27SH (Scheme 1), Galfβ acceptor 1
54
was glycosylated with Galpα donor 350 to furnish the fully
protected disaccharide 4 in 65% yield. The silylene group was
removed using HF·pyridine complex to give compound 6 in
65% yield, and then, the isopropylidene group was hydrolyzed
with aqueous trifluoroacetic acid (TFA) to afford allyl
glycoside 7 in 90% yield. The radical addition of thioacetic
acid (AcSH) to 7 in dry THF furnished thioester 8 in 85%
yield. Complete deacylation under Zempleń conditions
provided the target disaccharide G27SH quantitatively, which
oxidized to disulfide (G27S)2.
The trisaccharide 3-thiopropyl α-D-galactopyranosyl-(1→3)-
β-D-galactofuranosyl-(1→3)-β-D-mannopyranoside G30SH was
synthesized by two consecutive glycosylation steps. First, the
Galfβ acceptor 255−57 was glycosylated with Galpα donor 354
with high stereoselectivity to produce disaccharide 5 in 67%
yield. This donor was used to regioselectively glycosylate
mannosyl acceptor 958 to yield trisaccharide 10 in 47% yield. A
similar regioselective glycosylation was previously reported on
an analogous mannosyl acceptor.48 Afterward, the silylene
protecting group was removed with HF·pyridine complex, and
without purification, both the benzylidene and isopropylidene
groups were removed by acid-catalyzed hydrolysis to give
compound S7 in 48% yield over two steps. The radical
addition of AcSH to the allyl glycoside was achieved in 85%
yield to provide thioester S8.54 Finally, global removal of all
ester groups under Zempleń conditions furnished the desired
trisaccharide G30SH quantitatively (Scheme 1), which oxidized
to disulfide (G30S)2.
Scheme 2. Conjugation of Glycans and Maleimide Derivatized BSA 14 to Produce NGPs
aTCEP·HCl, phosphate buffer pH 7.2, rt, 2 h.
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Figure 2. Chemiluminescent ELISA reactivity of NGP27b, NGP28b, and NGP30b with sera from individual patients with L. major or L. tropica
infection or with heterologous disease. Sera (at 1:800 dilution) from individual patients with active L. major or L. tropica infection or with
heterologous disease (with other skin conditions) were evaluated against NGP27b, NGP28b, and NGP30b, each at 25 ng/well. Chemiluminescent
ELISA was performed as described in the Supporting Information (“Chemiluminescent ELISA”). (a) Grouped scatter plot analysis of sera from L.
major or L. tropica infections or heterologous diseases (Het.) with NGP27b, NGP28b, or NGP30b. The Y-axis values are in log2 scale. Ci, initial
cutoff value (titer = 1.000), calculated as described in the Supporting Information. CL.t., adjusted cutoff value, calculated based on the ROC and
TG-ROC curve analysis data (b, c), for the comparison between sera from L. major vs L. tropica infections. CHet., adjusted cutoff value for the
comparison between sera from L. major infection vs heterologous diseases. Statistical analysis: nonparametric Mann−Whitney test. Significance
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The trisaccharide 3-thiopropyl α-D-galactopyranosyl-(1→6)-
α-D-galactopyranosyl-(1→3)-β-D-galactofuranoside G28SH was
synthesized from disaccharide 4. We found by serendipity that
the 4,6-O-DTBS ring of disaccharide 4 can be regioselectively
opened with HF·pyridine rendering only position 4 of the α-
Gal residue protected as a di-tert-butylfluorosilyl ether and
OH-6 unprotected. A similar regioselective ring-opening of a
3,5-O-DTBS group of a galactofuranoside with tetrabutylam-
monium fluoride (TBAF) had been reported;59 however, the
4,6-O-DTBS group of a galactopyranoside resists reaction with
TBAF, even when used in large excess. Conversely, 1.2 equiv of
HF·pyridine complex at 0 °C opened the silylene ring of
disaccharide 4 within 6 h. The reaction time could be reduced
to only 2 h by using HF·pyridine in excess at 0 °C and
immediate quenching with aqueous saturated NaHCO3
solution. The resulting disaccharide 11 was obtained in 60%
yield, and we envisioned it to be used as a glycosyl acceptor.
One concern was that the bulky silyl group at position 4 could
potentially hinder the glycosylation at OH-6; however, donor
350 was able to glycosylate acceptor 11 to provide the fully
protected trisaccharide 12, with an exclusive α-stereoselectivity
in an acceptable yield of 50%. Subsequent treatment with HF·
pyridine complex in excess from 0 °C to room temperature
(rt) removed the silyl and silylene groups to produce
trisaccharide 13 in 88% yield. Acid-catalyzed hydrolysis of
the isopropylidene group of 13 produced compound S5 in
77% yield, and the thioester derivative S6 was prepared by the
radical addition of AcSH in 93% yield.54 Global deprotection
under Zempleń conditions furnished the target 3-thiopropyl
trisaccharide G28SH quantitatively (Scheme 1), which oxidized
to disulfide (G28S)2.
Reduction of the disulfides (G27S)2, (G28S)2, and (G30S)2
with TCEP·HCl and conjugation to commercial maleimide-
derivatized BSA 14 produced the conjugates NGP27b,
NGP28b, and NGP30b, respectively (Scheme 2). The average
number of glycans conjugated per BSA molecule was estimated
by matrix-assisted laser/desorption ionization time-of-flight
mass spectrometry (MALDI-TOF-MS). Using the known
masses of glycans and linker, the payloads (n = 29, 25, and 28)
were calculated by subtracting the average mass of BSA from
the average masses of NGP27b, NGP28b, and NGP30b,
respectively (Figures S1−S3).54
With the NGP antigens in hand, IgG antibody responses of
serum samples from patients with acute L. major or L. tropica
infection, confirmed by dermatological examination, micro-
scopic analysis of lesion aspirate, and PCR-restriction fragment
length polymorphism-based analysis using the rDNA internal
transcribed spacer 1 (rDNA-ITS1) (ITS1-PCR-RFLP),60
could now be studied by chemiluminescent ELISA. The
serum samples of patients had been collected from 81
individuals with active L. major infection and 15 individuals
with active L. tropica infection, from the areas Al-Ahsa and Asir
in Saudi Arabia, where L. major and L. tropica infections are
endemic.29 In addition, pooled sera of 10 healthy individuals,
designated normal human serum (NHS), from England, UK,
as well as sera from 24 individuals with heterologous diseases
from the Al-Ahsa governorate, Saudi Arabia, were also
integrated in the study (more detail about the study population
and diagnostic methods is provided in the Supporting
Information, “Ethics Statement and Cohort Description,
Chemiluminescent ELISA”).
The heterologous sera were from patients who had skin
conditions other than CL. Therefore, these sera represent a
real-life, non-CL negative control group, relevant to what a
physician may encounter, from which a useful CL BMK must
be able to distinguish. Since all NHS contains anti-α-Gal
antibodies directed against α-Gal-containing lipopolysacchar-
ides of Gram-negative enterobacteria,61,62 a small amount of
cross-reactivity between NHS anti-α-Gal antibodies and the L.
major-derived glycostructures might be expected, as previously
observed with purified L. major type-2 GIPL-1, GIPL-2, and
GIPL-3.39 In order to ensure that chemiluminescent ELISA
responses were not a result of antibody binding to BSA or the
cross-linker, 2-MEb, obtained by conjugating 2-mercaptoetha-
nol (2-ME) to maleimide-derivatized BSA 14 (Figure S1c),
was used as a negative control antigen. In order to identify a
suitable protocol for the chemiluminescent ELISA, serum
pools were prepared and cross-titrated against different
concentrations [ng/well] of the three NGPs and 2-MEb.
Figure S5 shows that the L. major serum pool at different
dilutions (1:400−1:3200) exhibited a high IgG antibody
reactivity to NGP27b, NGP28b, and NGP30b, at different
concentrations (3−400 ng/well), whereas the L. tropica and
NHS (healthy) serum pools showed a significantly lower
antibody reactivity at different serum dilutions and antigen
concentrations. The cross-titration experiment revealed that a
serum dilution of 1:800 and an antigen loading of 25 ng/well
exhibited the highest differential antibody reactivity between
the L. major-positive serum pool and serum pools from L.
tropica-positive or healthy individuals. Under these conditions,
the reactivity ratios between L. major and healthy serum pools
were ∼6-, ∼9-, and ∼56-fold for NGP27b, NGP28b, and
NGP30b, respectively. Comparing L. major vs L. tropica serum
pools, the reactivity ratios were ∼90-, ∼9-, and ∼16-fold for
NGP27b, NGP28b, and NGP30b, respectively. As expected,
the negative control 2-MEb showed no or little reactivity with
all pooled sera, indicating that no significant antibody binding
occurred to BSA or the cross-linker (Figure S5).
Next, NGP27b, NGP28b, and NGP30b were tested as
potential BMKs for the accurate diagnosis of L. major
infections and, in particular, differentiating these from
heterologous diseases, which is a major issue in clinical
settings in some endemic and nonendemic regions, where
there is a high migration of CL patients from affected areas.
Figure 2. continued
level: p < 0.05. ****, p < 0.0001; ns, nonsignificant. (b) Receiver-operating characteristic (ROC) curves for NGP27b, NGP28b, and NGP30b,
comparing the reactivity of sera from L. major vs L. tropica infections (top row) or sera from L. major infections vs heterologous diseases (bottom
row), using the data depicted in the scatter plots (a). AUC, area under the curve, is indicated (gray area). In parentheses, 95% confidence interval
values are indicated. (c) A TG-ROC curve analysis was performed by plotting the ROC data (b) for sensitivity (Se) and specificity (Sp), as
described by Greiner et al.64 Shaded area indicates the cutoff value interval where Se or Sp could reach 100%. The Se (black) and Sp (purple) raw
data points are represented as fine lines, whereas the fitted data are indicated as thick lines. Vertical black line, original titer cutoff value (Ci =
1.000); vertical dotted green line, adjusted cutoff value for the comparison of L. major infections vs heterologous diseases; vertical dashed red line,
adjusted cutoff value for the comparison of L. major vs L. tropica infections. The adjusted cutoff values are indicated in green or red.
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Second, we evaluated these NGPs for their utility for
distinguishing L. major from L. tropica infections, which is
another challenge in similar clinical settings. To that end, we
assessed the three NGPs by chemiluminescent ELISA, using
conditions previously established (Figure S5). We assayed
individual sera from CL patients chronically infected with L.
major (n = 81) or L. tropica (n = 15) or patients with
heterologous diseases (n = 24) (Table S1). We initially used a
chemiluminescent ELISA titer cutoff of 1.000, which was
determined in each immunoassay microplate by using a pool of
negative control sera (healthy individuals from the UK, n =
10), in duplicate or triplicate, as described in detail in the
Supporting Information (“Chemiluminescent ELISA”) (Figure
2A and Figure S6a). Our data showed that NGP27b diagnosed
as positive 77/81 (sensitivity = 95.3%) of the sera from
patients with L. major infection, previously confirmed by
dermatological examination and laboratory assays (lesion
aspirate microscopy and ITS1-PCR-RFLP analysis)63 (Sup-
porting Information, “Cohort description”) (Figure 2a; Tables
1 and 2). On the other hand, NGP28b and NGP30b
diagnosed as L. major-positive 70/81 and 73/81 (sensitivity
= 88.0% and 91.0%), respectively. We also evaluated the three
NGPs for specificity by comparing sera from L. major
infections with sera from heterologous diseases or L. tropica
infections. When we assessed L. major-positive sera vs sera
from heterologous diseases, NGP27b, NGP28b, and NGP30b
exhibited a specificity of 82.8%, 80.0%, and 80.0%, respectively
(Table 2). When we compared L. major-positive vs L. tropica-
positive sera, we found that NGP27b, NGP28b, and NGP30b
showed a specificity of 93.8%, 88.2%, and 79.0%, respectively
(Table 2). Conversely, individual or pooled sera from L. major
or L. tropica infections or heterologous diseases showed very
weak reactivity (mostly below the titer cutoff of 1.000) with
the negative control antigen (2-MEb), strongly indicating that
the antibody reactivity of all tested sera to the linker or the
BSA carrier protein was negligible (Figure S6b).
To compare the usefulness of the three NGPs for correctly
discriminating true-positive (TP) from false-positive (FP)
results, at various threshold (cutoff) values, we plotted
receiver-operating characteristic (ROC) curves (Figure 2b).
The area under the curve (AUC) values of the ROC curves for
NGP27b (0.9421), NGP28b (0.9216), and NGP30b
(0.9159), in the comparison of serum samples from L. major
infections vs heterologous diseases, indicated that NGP27b
exhibited higher sensitivity and specificity than NGP28b and
NGP30b (Figure 2b, top graphs; Table 2). In the comparison
of serum samples from L. major vs L. tropica infections, the
AUC values for NGP27b (0.9757), NGP28b (0.9280), and
NGP30b (0.8951) indicated the same trend (Figure 2b,
bottom graphs; Table 2). Taken together, our initial data
indicated that NGP27b showed a higher sensitivity and
specificity than NGP28b and NGP30b.
Table 1. Reactivity of Sera from L. major Infections, Heterologous Diseases, and L. tropica Infections with NGP27b, NGP28b,
and NGP30b
NGP27b NGP28b NGP30b
infection/disease n positive negative positive negative positive negative
Original Valuesa
L. major 81 77 4 70 11 73 8
heterologous 24 5 19 6 18 6 18
L. tropica 15 1 14 2 13 4 11
Post-TG-ROC Analysisb
L. major 81 76 5 65 16 70 11
heterologous 24 4 20 7 17 0 24
L. tropica 15 0 15 3 12 1 14
aValues calculated based on the initial cutoff value (Ci ; titer = 1.000) (Figure 2a), as described in the Supporting Information (“Chemiluminescent
ELISA”). bValues calculated based on the TG-ROC analysis (Figure 2c; Tables S1 and S2).
Table 2. Sensitivity, Specificity, and Other Diagnostic Parameters of NGP27b, NGP28b, and NGP30b
L. major infections vs heterologous diseases L. major vs L. tropica infections
NG27b (%) NGP28b (%) NGP30b (%) NG27b (%) NGP28b (%) NGP30b (%)
Original Valuesa
sensitivityb 95.3 88.0 91.0 95.3 88.0 91.0
specificityc 82.8 80.0 80.0 93.8 88.2 79.0
FPRd 17.2 20.0 20.0 6.2 11.8 21.0
PPVe 94.2 93.1 93.1 98.8 97.6 95.3
NPVf 85.7 68.6 75.0 79.0 57.7 65.2
Post-TG-ROC Analysisg
sensitivity 94.2 83.5 88.0 95.3 88.0 88.0
specificity 85.7 92.3 100.0 100.0 88.2 93.8
FPR 14.3 7.7 0.0 0.0 11.8 6.2
PPV 95.3 92.0 100.0 100.0 96.4 98.8
NPV 82.8 60.0 75.0 75.0 48.4 57.7
aValues calculated based on the initial cutoff value (Ci ; titer = 1.000) (Figure 2a), as described in the Supporting Information (“Chemiluminescent
ELISA”). bSensitivity = true positive (TP)/TP + false negative (FN). cSpecificity = true negative (TN)/TN + false positive (FP). dFalse-positive
rate = 100 − specificity. ePositive predictive value = TP/TP + FP. fNegative predictive value = TN/TN + FN. gValues calculated based on the TG-
ROC analysis (Figure 2c; Tables S1 and S2).
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Next, to fine-tune the initial titer cutoff value (Ci; Figure 2a)
for each NGP, we performed a two-graph ROC (TG-ROC)
analysis by plotting the ROC data (Figure 2b) for sensitivity
(Se) and specificity (Sp) as a function of the cutoff value, as
described by Greiner et al.64 (Figure 2c). The selection of the
cutoff value is always a trade-off between sensitivity and
specificity, and it depends on the context in which the
diagnostic BMK is to be applied. Since CL is caused by L.
major or L. tropica in endemic countries like Saudi Arabia,
where little geographical overlap of the two infections exists,
the utility of a new diagnostic BMK test is not a high priority.
However, in areas where L. major and L. tropica infections
coexist, for instance, in conflict-affected countries (e.g.,
Afghanistan, Syria, Lebanon)65,66 and nonendemic regions
(e.g., Europe), with high migration from affected areas,67,68
there is an urgent need for new diagnostic BMKs that could
accurately diagnose CL from non-CL conditions (i.e.,
dermatological diseases) and discriminate CL caused by
different Leishmania species. In this context, a high specificity
is preferred over high sensitivity for any potential new
diagnostic BMK for CL.64 When comparing L. major infections
vs heterologous diseases, an adjusted titer cutoff value for
NGP27b of 1.140 (instead of 1.000) slightly decreased
sensitivity to 94.2% (from 95.3%) but increased specificity to
85.7% (from 82.8%) (Table 2). When comparing L. major vs
L. tropica infections, we noticed that an adjusted titer cutoff
value for NGP27b of 1.045 afforded a perfect specificity of
100% (from 93.8%), while maintaining the same high
sensitivity of 95.3% (Figure 2a,c; Table 2). For NGP28b, in
the comparison of L. major infections vs heterologous diseases,
an adjusted titer cutoff value of 1.600 gave a lower sensitivity of
83.5% (from 88.0%), while the specificity considerably
improved to 92.3% (from 80.0%). Nevertheless, when
comparing L. major vs L. tropica infections, we found that
the original NGP28b titer cutoff value of 1.000 could not be
significantly improved without drastically affecting the
sensitivity. Therefore, we maintained the same cutoff value of
1.000 (Figure 2a,c; Table 2). Finally, for NGP30b, when we
compared L. major infections vs heterologous diseases, an
adjusted titer cutoff value of 1.465 gave a sensitivity of 88%
(from 91%) but significantly increased the specificity to 100%
(from 80.0%) (Figure 2a,c; Table 2). When comparing L.
major vs L. tropica infections with NGP30b, the same adjusted
titer cutoff value of 1.465 decreased the sensitivity to 88%
(from 91.0%) but significantly increased the specificity to
93.8% (from 79.0%).
Based on the TG-ROC analysis data with the adjusted titer
cutoff values, we can propose an algorithm with the two NGPs
that exhibited the best outcomes in terms of sensitivity and
specificity, i.e., NGP27b and NGP30b, to consecutively screen
sera from patients who could be infected with either L. major
or L. tropica, or affected with a confounding, non-CL
dermatological condition(s) (Figure 3). First, the serum
would be screened by chemiluminescent ELISA with
NGP27b. A positive result would indicate L. major infection
or heterologous disease, whereas a negative result would
indicate L. tropica infection or heterologous disease. A sample
with a positive result would undergo a second chemilumines-
cent ELISA now using NGP30b to discriminate between L.
major infection and heterologous disease. Importantly, the
proposed algorithm should complement the patient’s clinical
assessment and history.
Although all three NGPs exhibited similar trends regarding
their immunoreactivity with L. major sera, on average,
NGP30b showed titers about twice as high as those of
NGP27b and NGP28b (Figure 2a). This could be explained
by the fact that NGP30b contains a larger portion of the
glycotope of type-2 GIPL-2, which has been shown to be
strongly recognized by sera from L. major patients.38
Regardless of the NGP tested, we observed a small cross-
reactivity with sera from L. tropica infections and heterologous
diseases. A plausible explanation for such a cross-reactivity
could be the presence of natural anti-α-Gal antibodies,
abundantly present in the serum of all individuals, as reported
by Galili et al.61,62 These antibodies cross-react with the so-
called Galili epitope or trisaccharide (Galα1,3Galβ1,4Glc-
NAcβ) and other glycans containing terminal, nonreducing α-
G a l e p i t o p e s , i n p a r t i c u l a r m e l i b i o s e
(Galα1,6Glc).12,18,46,52,53,69 In fact, both the Galili trisacchar-
ide and melibiose are regularly used for the purification of
natural anti-α-Gal antibodies,12,70 which could explain at least
in part the cross-reactivity observed here with NGP27b
(Galα1,3Galfβ-BSA) and NGP30b (Galα1,3Galfβ1,3Manα-
BSA) and NGP28b (Galα1,6Galα1,3Galfβ-BSA), which
contain terminal α-Gal residues with the same linkages as
observed in the Galili trisaccharide and melibiose.
Similar bottom-up reversed immunoglycomics studies for
the discovery of glycotopes and BMKs have been previously
described in the trematode Schistosoma mansoni and
kinetoplastids closely related to L. major, i.e., T. cruzi and L.
braziliensis. For instance, Naus and colleagues used surface
plasmon resonance (SPR) to evaluate three NGPs containing




with two cohorts (n = 235) from an endemic area in
Kenya.71 They found that LDN-DF was the most antigenic
NGP, being recognized especially by young children with early
infection. In a subsequent study, the same group of
investigators and collaborators, using monoclonal antibodies
(mAbs), raised against the immunogenic O-glycan of the S.
mansoni circulating anodic antigen (CAA) repeating unit ([ →
6)-[β-D-GlcpA-(1→3)]-β-D-GalpNAc-(1→ ]n) (anti-CAA
mAbs), showed that this disaccharide was strongly recognized
by urine and serum from patients with schistosomiasis.72 To
get insight into the specificity of these anti-CAA mAbs, a series
Figure 3. Algorithm for discriminating L. major infection from L.
tropica infection and heterologous disease, using NGP27b and
NGP30b sequentially in chemiluminescent ELISA.
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of synthetic di-, tri-, and tetrasaccharide analogues of the CAA
repeating unit were evaluated as NGPs by sandwich ELISA and
SPR.73 Those authors showed that these mAbs were more
reactive to the repeating unit dimer than to the monomer,
indicating a potential application of these mAbs as diagnostic
tools to detect circulating S. mansoni antigens.
In a more recent study on CL caused by New-World L.
braziliensis, de Souza and colleagues analyzed the serum
immunoreactivity to three commercial NGPs (non-Leishma-
nia-derived) containing terminal, nonreducing Galpα1,3Galpβ-
based glycotopes by chemiluminescent ELISA, using sera from
(i) L. braziliensis-caused CL patients, all with active lesion,
subjected or not to treatment, or undergoing treatment; (ii)
healthy individuals from endemic and nonendemic areas in
Brazil; and (iii) individuals with heterologous diseases (CD,
hepatitis B or C, tuberculosis, or syphilis).74 Interestingly, they
found that the highest sensitivity and specificity were observed
to the trisaccharide Galpα1,3Galpβ1,4GlcpNAcβ (Galili’s
trisaccharide), which has not yet been described in L.
braziliensis and is known to react very strongly with anti-α-
Gal Abs from CD patients.52,53,69 We had also previously
observed very high levels of anti-α-Gal Abs to the same NGP
containing the Galili’s trisaccharide in the serum of patients
with Old-World CL caused by L. major or L. tropica.45
Although we observed a significant difference in the anti-α-Gal
Ab titers between sera of L. major and L. tropica infections, no
differential diagnosis between these two infections was
achieved using the Galpα1,3Galpβ1,4GlcpNAc epitope. In a
more recent study, we assayed several other NGPs containing
other α-Gal-glycotopes linked to BSA, including α-Galp
(NGP3b), Galpα1,3Galpα (NGP17b), Galpα1,3Galpβ
(NGP9b), Galpα1,6[Galpα1,2]Galpβ (NGP11b), and Gal-
pα1,3Galpβ1,4Glcpβ (NGP1b).46 When assayed by chem-
iluminescent ELISA with sera from L. major-infected patients
with active CL lesion (n = 17) or cured (n = 29) or sera from
heterologous diseases, the most promising diagnostic potential
(AUCROC = 0.8) was observed with NGP3b (α-Galp−BSA).
Although this AUC value is considered acceptable for a
diagnostic test, a higher accuracy (AUC = 0.9−1.0), as we
observed in most ROC curves in this study, is desirable.75,76
Moreover, we and others have also been developing a similar
reverse immunoglycomics approach for the development of
diagnostic and/or prognostic tools (for early assessment of
chemotherapeutic outcomes) in CD, using NGPs displaying
synthetic terminal, nonreducing α-Galp glycotopes derived
from T. cruzi or recognized by patients with chronic
CD.52,53,69,77,78 These studies have shown very promising
results with highly immunogenic synthetic α-Gal glycotopes as
BMKs for diagnosis and follow-up of chemotherapy in the
context of CD. However, all potential BMKs revealed by the
reverse immunoglycomics approach, regardless of the disease,
need to be extensively validated using a more comprehensive
and larger panel of sera of homologous and heterologous
diseases and healthy individuals under strict clinical laboratory
and/or field settings.
■ CONCLUSION
The chemical synthesis of α-Gal-containing oligosaccharides
and their immunological evaluation with sera from OWCL
patients enabled the identification of diagnostic BMKs for
distinguishing OWCL caused by L. major from heterologous
diseases and from L. tropica infections. The synthetic targets
were the 3-thiopropyl glycosides of Galpα1,3Galfβ (G27SH),
Galpα1,3Galfβ1,3Manα (G30SH), and Galpα1,6Galpα1,3Galfβ
(G28SH) equipped with a handle for conjugation. These
oligosaccharides correspond to the terminal di- and trisacchar-
ide moieties of GIPL-2 and the terminal trisaccharide of GIPL-
3, respectively, which are abundantly expressed in L. major but
absent (or much less abundant) in L. tropica. The 4,6-O-DTBS
protecting group of Galp played two important roles in their
synthesis: (a) it allowed for stereoselective α-galactosylation;50
and (b) it underwent a regioselective ring-opening reaction
producing a new Gal acceptor in a single step, which allowed
for a convenient synthesis of G28SH. Conjugation of the
saccharides G27SH, G28SH, and G30SH to maleimide-
derivatized BSA produced NGP antigens for chemiluminescent
ELISA. The two NGPs, NGP27b and NGP30b, both derived
from L. major GIPL-2, exhibited 100% specificity for the
distinction of L. major from L. tropica infections (NGP27b)
and heterologous diseases (NGP30b). Therefore, sera of
patients with skin lesions that are suspicious for OWCL can be
subjected to two consecutive chemiluminescent ELISA tests,
which will diagnose an L. major infection with a very high level
of confidence. These NGPs could potentially be used to
develop a species-specific lateral flow test for OWCL, which is
important for informing best treatment options. This is
especially relevant in areas of population displacement in the
Middle East with large numbers of refugees who migrated from
OWCL-endemic areas.
The reversed immunoglycomics approach presented here
shows that glycotope and diagnostic BMK discovery does not
necessarily require cultivation of large amounts of parasite,
isolation, and analysis of glycans from the highly diverse and
heterogeneous glycocalyx. Instead, one can take advantage of
known structural information and probe the antigenicity of
small synthetic glycan partial structures in serological assays
using patient sera. Taken together, our results suggest that α-
Gal glycotopes of other closely related kinetoplastid (i.e., T.
cruzi) and New-World Leishmania species (e.g., L. braziliensis
and L. mexicana)10,23,39 and as-yet unidentified microbiome-
derived α-Gal glycotopes that elicit anti-α-Gal Abs present in
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